Most people hope these new weight-loss injections will be a short-term fix—but the emerging evidence suggests they may actually be a long-term commitment for many patients.
A recent study following people on the GLP-1–based drug tirzepatide found that the majority who initially lost weight later gained a significant portion of it back after stopping the medication. Of the 308 people who had benefited from the drug, 254 of them—about 82 percent—regained at least a quarter of the weight they had lost by week 88. Even more striking, 177 people, or 57 percent, put back on at least half of the lost weight, and 74 people, roughly 24 percent, regained three-quarters or more. As the weight crept back, many of the improvements in heart and metabolic health started to fade, suggesting a strong link between ongoing treatment and sustained health benefits.
The small group that broke the pattern
But here’s where it gets controversial: not everyone followed that pattern of regain. A smaller subset—54 out of the 308 participants, or about 17.5 percent—did not put back on a large amount of weight, gaining less than 25 percent of what they had lost. In this group, some health measures did worsen after they stopped the medication, but the picture was more mixed. Their blood pressure tended to rise somewhat, yet their cholesterol levels did not show a major overall increase. Interestingly, around a dozen people in the study—about 4 percent—actually continued to lose weight even after discontinuing the drug, which raises big questions about what makes their bodies respond so differently.
And this is the part most people miss: the researchers could not find clear reasons why these 54 individuals did so well after stopping treatment. According to their analysis, there were no obvious differences in age, sex, or clinical history that set them apart from the others. That means there may be hidden biological, behavioral, or environmental factors at play that science has not fully uncovered yet. The takeaway is that the way people respond after coming off these drugs may be far more individual than current guidelines capture, underscoring how much more research is needed.
A grim outlook for easy “off-ramps”
Looking at the results as a whole, the study paints a fairly bleak picture for anyone hoping to use anti-obesity medications briefly and then maintain all the benefits without continued treatment. For most participants, stopping tirzepatide led to meaningful weight regain and a rollback of improvements in cardiovascular and metabolic health. This suggests that for many people, these drugs may need to be viewed less like a short-term diet aid and more like ongoing therapy for a chronic condition.
One important detail is that participants in this study stopped the drug abruptly, rather than gradually tapering down their dose. In real life, many patients—and clinicians—are interested in a slower, stepwise reduction, lowering the dose over time to see whether the body can adapt and maintain the results. At the moment, however, there is very little strong data to show how well this tapering strategy works or exactly how it should be done. On top of that, a gradual approach might not even be possible for people who suddenly lose access, whether because of cost, supply issues, or changes in insurance coverage.
Possible strategies for coming off GLP-1 drugs
Experts have suggested that if someone plans to try coming off these medications, it may help to ramp up healthy lifestyle habits ahead of time. That might include increasing physical activity, tightening up calorie intake, and building consistent routines around sleep and stress management in anticipation of reducing or stopping the drug. The idea is to have strong behavioral supports in place to reduce the risk of rapid regain once the medication is withdrawn, although robust evidence for the best exact protocol is still limited.
Beyond finding better off-ramps, researchers are also calling for more information on what happens to the body as weight goes up and down when people cycle on and off treatment. One concern comes from at least one study suggesting that when weight is regained after intentional weight loss, a greater share of that weight may come back as fat rather than lean mass. If that pattern holds true for people using GLP-1–based medications, it could mean that repeated cycles of loss and regain might actually reshape body composition in a way that is harmful over time.
Are these drugs a lifelong therapy?
For now, leading voices like Oczypok and Anderson advise that clinicians talk openly and cautiously with patients about what these findings may mean for the future. They emphasize that the growing evidence base supports treating anti-obesity medications more like long-term therapies for a chronic disease, similar to how doctors approach drugs for conditions such as high blood pressure or diabetes. That does not mean every patient must stay on them forever, but it does suggest that starting these medications should come with a realistic conversation about the likelihood of needing ongoing treatment to maintain the benefits.
Here’s the uncomfortable question: if these medications work only as long as you stay on them, should they be thought of more like weight-loss tools or like lifelong maintenance drugs for obesity as a chronic illness? Do you agree that long-term use is a reasonable trade-off for better health, or do you worry about the medical and financial consequences of staying on them indefinitely? Share whether you think this shift toward “forever medication” for obesity is empowering, concerning, or something in between—and why.
